Adana Alexander
Investor Relations Consultant
Replay available
Cytosorbents Corporation (NASDAQ: CTSO) Q2 2025 earnings conference call, held 2025-08-07. Replay captured from the company's public earnings webcast.

Investor Relations Consultant
Chief Executive Officer
Chief Financial Officer
Analyst, Jefferies
Analyst, SACS Research
Good day, ladies and gentlemen, and welcome to the Q2 2025 Earnings Conference Call for CITO Servants Corp. At this time, all lines are in listen-only mode. Following the presentation, we'll conduct a question and answer session. If at any time during this call you require automated assistance, please press star zero for the operator. This call is being recorded on Wednesday. Please, sorry, I would like to return the conference over to Adana Alexander, Investor Relations Consultant. Please go ahead. Thank you, Sergio, and good afternoon, everyone. Welcome to Finest Open's second quarter 2025 financial results and recent business highlights conference call. Joining me today from the company for the prepared remarks are Dr. Philip Chan, Chief Executive Officer, and Pete Mariani, Chief Financial Officer. Before I turn the call over to Dr. Chan, I'd like to remind listeners that during the call, management prepared remarks may contain forward-looking statements which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore, the company claims protection under the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today. The forward-looking statements we make reflect our views and estimates as of today, August 7th, 2025. and we assume no obligation to update these projections in the future as market conditions change. During today's call, we will have an overview presentation covering the operating and financial highlights for the second quarter 2025. Following the presentation, we will open the line to analysts for questions. And now, it's my pleasure to turn the call over to Dr...